- High vs low expression of androgen receptor (AR) in nonmetastatic breast cancer is an independent prognostic marker of superior survival.
Why this matters
- Findings suggest that AR may be clinically useful as a prognostic marker.
- Prospective cohort study comparing high vs low AR expression, using immunohistochemistry on tissue microarrays from 395 patients with breast cancer (excluding stage IV) at a Korean center (1999-2012).
- Funding: Korea Breast Cancer Foundation; others.
- Mean follow-up: OS, 120.8±51.0 months; DFS, 87.5±50.5 months.
- High vs low AR expression was associated with better OS (P=.047), DFS (P=.004), and systemic recurrence-free survival (P=.027).
- In multivariate analysis, high AR was an independent prognostic factor for superior OS (HR, 0.586; P=.015) and DFS (HR, 0.430; P<.001>
- Features of the subgroup showing high AR as an independent prognostic factor for DFS were positive hormone receptor and negative human epidermal growth factor receptor 2 (P=.026).
- Single center.